Last reviewed · How we verify
Tamoxifen dose adjustment
At a glance
| Generic name | Tamoxifen dose adjustment |
|---|---|
| Sponsor | Nalagenetics Pte Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PHASE2)
- CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population (NA)
- Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels (NA)
- Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PHASE2)
- A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamoxifen dose adjustment CI brief — competitive landscape report
- Tamoxifen dose adjustment updates RSS · CI watch RSS
- Nalagenetics Pte Ltd portfolio CI